Compositions and methods for treating or preventing exercise-induced muscle fatigue and / or for resisting exercise-induced muscle fatigue using at least one of oleuropein or metabolites thereof

By taking oleurin or its metabolites before, during or after exercise, combined with calcium and other nutrients, the problem of muscle fatigue caused by exercise is solved, and the muscles' anti-fatigue ability and exercise performance are significantly improved.

CN119013029APending Publication Date: 2024-11-22SOCIETE DES PRODUITS NESTLE SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033981.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-05-04
Filing Date
2023-05-02
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent or treat muscle fatigue caused by exercise, especially in middle-aged and elderly people, resulting in loss of strength and physical strength.

Method used

Oleurin or its metabolite is used and administered before, during or after exercise by oral administration to reduce the frequency and severity of muscle fatigue and improve resistance to muscle fatigue caused by exercise. Oleurin can be combined with calcium and added to food ingredients containing proteins, carbohydrates and fats, or used as a separate unit dosage form.

Benefits of technology

It significantly improves the muscle's fatigue resistance, delays the process of muscle mass reduction, and enhances exercise ability, especially in resistance exercise, anaerobic or repeated full-speed running exercises and endurance exercises.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005082545870000011
    Figure HDA0005082545870000011
  • Figure HDA0005082545870000021
    Figure HDA0005082545870000021
  • Figure HDA0005082545870000031
    Figure HDA0005082545870000031
Patent Text Reader

Abstract

A method of preventing or treating exercise-induced muscle fatigue and / or for resisting exercise-induced muscle fatigue, the method comprising orally administering to a subject at least one of oleuropein or a metabolite thereof before, during and / or after exercise. A unit dosage form containing an effective amount of at least one of oleuropein or a metabolite thereof, for administration of said unit dosage form before, during and / or after exercise, thereby preventing or treating muscle fatigue caused by said exercise and / or for resisting muscle fatigue caused by exercise. A method of preparing a composition for preventing or treating exercise-induced muscle fatigue and / or for resisting exercise-induced muscle fatigue, the method comprising adding an effective amount of at least one of oleuropein or a metabolite thereof to at least one component selected from the group consisting of protein, carbohydrate and fat. The exercises are preferably one or more of 1) anti-resistance exercises, 2) anaerobic or repeated full-speed running exercises, or 3) endurance exercises.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] The present disclosure generally relates to compositions and methods for using oleuropein or at least one of its metabolites to treat or prevent exercise-induced muscle fatigue and / or for resisting exercise-induced muscle fatigue, such as from one or more of: 1) resistance exercise, 2) anaerobic or repetitive sprint-type exercise, or 3) endurance exercise.

[0002] "Muscle fatigue" refers to a decrease in contractile force in one or more muscles due to insufficient substrate within the muscle fiber and / or accumulation of metabolites within the muscle fiber that interfere with the release of calcium or the ability of calcium to stimulate muscle contraction. Age-related loss of muscle mass is due to interrelated factors - lifestyle, changes in muscle structure and metabolic changes, and is responsible for nearly all strength and power losses in middle-aged and elderly people, with an accompanying increase in muscle fatigue. Summary of the invention

[0003] The experimental data disclosed below show the beneficial effects of oleuropein in terms of exercise-induced muscle fatigue. Therefore, in some embodiments, the present disclosure provides a method for preventing (e.g., reducing the incidence, frequency and / or severity) or treating exercise-induced muscle fatigue. Additionally or alternatively, the method provides resistance to exercise-induced muscle fatigue. The method includes orally administering to an individual at least one of oleuropein or its metabolites (e.g., an effective amount) before, during and / or after the individual exercises.

[0004] Preferably, the exercise is at least one of the following: 1) resistance exercise, 2) anaerobic or repeated full-speed running type exercise, 3) endurance exercise. Preferably, at least a portion of the muscle cells are part of a skeletal muscle selected from the group consisting of gastrocnemius, tibialis, soleus, extensor digitorum longus (EDL), biceps femoris, semitendinosus, semimembranosus, gluteus maximus and combinations thereof.

[0005] In one embodiment, oleuropein or at least one of its metabolites is administered in at least one dose during at least one time period selected from: (i) a pre-exercise time between one hour before starting exercise and one second before starting exercise, such as between thirty minutes before starting exercise and one minute before starting exercise; (ii) an exercise time between starting exercise and ending exercise; and (i) a post-exercise time between one second after ending exercise and one hour after ending exercise, such as between one minute after ending exercise and thirty minutes after ending exercise.

[0006] In one embodiment, the metabolite of oleuropein is selected from the group consisting of oleuropein aglycone, hydroxytyrosol, homovanillyl alcohol, isohomovanillyl alcohol, glucuronidated forms thereof, sulfated forms thereof, derivatives thereof, and mixtures thereof.

[0007] In one embodiment, an effective amount of oleuropein or at least one of its metabolites is administered in a composition selected from the group consisting of a food composition, a beverage, a dietary supplement, a nutritional composition, a nutraceutical, a powdered nutritional product to be reconstituted with water or milk prior to consumption, a food additive, a medicament, a drink, a pet food, and combinations thereof.

[0008] In one embodiment, oleuropein or at least one of its metabolites is administered in a composition that also comprises calcium.

[0009] In one embodiment, an effective amount of oleuropein or at least one of its metabolites is administered in a food product further comprising a component selected from the group consisting of protein, carbohydrate, fat, and mixtures thereof.

[0010] In another embodiment, the present disclosure provides a unit dosage form comprising an effective amount of oleuropein or at least one of its metabolites for preventing (e.g., reducing the incidence, frequency and / or severity) or treating exercise-induced muscle fatigue and / or for resisting exercise-induced muscle fatigue.

[0011] In one embodiment, the unit dosage form consists essentially of oleuropein or at least one of its metabolites.

[0012] In one embodiment, the unit dosage form consists of at least one of oleuropein or a metabolite thereof and an excipient.

[0013] In one embodiment, the unit dosage form further comprises calcium. The unit dosage form may consist essentially of oleuropein or at least one of its metabolites and calcium. The unit dosage form may consist of oleuropein or at least one of its metabolites and an excipient, calcium.

[0014] In another embodiment, the present disclosure provides a method for preparing a composition for preventing (e.g., reducing the incidence, frequency and / or severity) or treating exercise-induced muscle fatigue and / or for resisting exercise-induced muscle fatigue. The method comprises: adding an effective amount of oleuropein or at least one of its metabolites to at least one component selected from protein, carbohydrate and fat. In one embodiment, the method further comprises adding calcium to at least one component.

[0015] In one embodiment, the method further comprises adding to at least one ingredient a food additive selected from the group consisting of acidulants, thickeners, buffers or agents for pH adjustment, chelating agents, colorants, emulsifiers, excipients, flavoring agents, minerals, osmotic agents, pharmaceutically acceptable carriers, preservatives, stabilizers, sugars, sweeteners, texturizers, vitamins, minerals, and combinations thereof.

[0016] Additional features and advantages are described herein, and will be apparent from the following figures and detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 The chemical structure of oleuropein is shown.

[0018] Figure 2 The metabolic pathways of oleuropein by mammalian and microbial enzymes in the present invention based on the research results reported in the literature are shown.

[0019] FIG3A shows the chemical structure of homovanillyl alcohol; and Figure 3B Its isomers (3-hydroxy-4-methoxyphenethyl alcohol or 3-hydroxy-4-methoxyphenethyl alcohol) are shown.

[0020] Figure 4 Figure showing that oleuropein increases mitochondrial calcium elevation in HeLa cells during stimulation. Statistical evaluation of the effect of oleuropein (10 μM, black) on the integrated mitochondrial calcium elevation induced by 100 μM histamine. The figure shows the average of 3 independent experiments. Results are expressed as mean + / - SEM. * indicates a statistically significant difference relative to control cells (white), P < 0.05 (Student's t-test).

[0021] Figure 5 Graph showing that oleuropein enhances mitochondrial calcium in caffeine-stimulated myotubes, which are distinct from human skeletal muscle myoblasts (HSMM). Statistical evaluation of the effect of oleuropein (10 μM, black) on the rise in integrated mitochondrial calcium induced by 5 mM caffeine. The graph shows the average of 6 independent experiments. Results are expressed as mean + / - SEM. * indicates a statistically significant difference relative to control cells (white), P < 0.05 (Student's t-test).

[0022] Figure 6 Figure showing that metabolites of oleuropein promote mitochondrial calcium in caffeine-stimulated HSMM myotubes. Statistical evaluation of the effect of 10 μM concentration of oleuropein and its metabolites on the increase in integrated mitochondrial calcium induced by 5 mM caffeine. The figure shows the average of 6 independent experiments. Right, selected metabolites. Results are expressed as mean + / - SEM. *Indicates statistically significant differences relative to control cells (white), P < 0.05 (one-way ANOVA test).

[0023] Figure 7 To show Ca 2+ Supplementation enhances mitochondrial Ca in C2C12-derived myotubes in a dose / response manner 2+Graph of the increase. Statistical evaluation of the effect of extracellular calcium abundance on the increase in integrated mitochondrial calcium induced by 5 mM caffeine. Right, calcium concentration in the culture medium (in mM). The graph shows the average of 12 measurements from 3 independent experiments. Results are expressed as mean + / - SEM. *Indicates a statistically significant difference relative to 0.5 mM calcium concentration in the culture medium (white), P < 0.05 (one-way ANOVA test).

[0024] Figure 8 Figure 2 shows that oleuropein rescues mitochondrial activation under calcium deficiency conditions in C2C12-derived myotubes. Statistical evaluation of the effect of 50 μM oleuropein on the integrated mitochondrial calcium increase induced by 5 mM caffeine. Right, calcium concentration in the culture medium (in mM). The figure shows the average of 12 measurements from 3 independent experiments. Results are expressed as mean + / - SEM. *Indicates a statistically significant difference relative to 0.5 mM calcium concentration in the culture medium (white), P < 0.05 (one-way ANOVA test).

[0025] Fig. 9 Figure showing that oleuropein and hydroxytyrosol promote the ATP synthase-dependent component of respiration during stimulation in myotubes differentiated from human skeletal muscle (HSM) myoblasts. Statistical evaluation of the effect of 10 μM hydroxytyrosol (grey bars) or 10 μM oleuropein (black bars) on the ATP synthase-dependent component of respiration in HSM myotubes, stimulated with 10 μM epibatidine and calculated from the data in the inset. Inset, respiration curve of human skeletal muscle myotubes. The compound is hydroxytyrosol or oleuropein. Oligomycin was used to determine the ATP synthase-dependent component of respiration in epipatidine-stimulated myotubes. The figure shows the average of 8 experiments. The results are expressed as mean + / - SEM. * indicates a statistically significant difference relative to the control (white bars), P < 0.05 (one-way ANOVA test).

[0026] Fig.10 Figure 2 shows that oleuropein increases ATP production in C2C12 derived myotubes stimulated with caffeine. Myotubes were incubated with oleuropein for 15 minutes, and then they were stimulated with 5 mM caffeine for 10 minutes. The figure shows the average of 8 experiments. The results are expressed as mean + / - SEM. * indicates a statistically significant difference relative to control cells (white), P < 0.05 (Student's t-test).

[0027] Fig.11Figure showing that oleuropein increases mitochondrial calcium uptake in isolated adult mouse muscle fibers transfected with the mitochondrial calcium sensor 4mtGCaMP6f (ex vivo). Fibers were treated with oleuropein. Three minutes later, cells were stimulated with 60 mM caffeine. Left: Representative traces of mitochondrial calcium uptake. Right: Mean of mitochondrial calcium peaks. Results are expressed as mean + / - SD. *Indicates statistically significant differences relative to control muscle fibers of >20 fibers per condition, P < 0.05 (Student's t-test).

[0028] Fig.12 Figure 2 shows that hydroxytyrosol increases mitochondrial calcium uptake in isolated adult mouse myofibers transfected with the mitochondrial calcium sensor 4mtGCaMP6f (ex vivo). Fibers were treated with hydroxytyrosol. Three minutes later, cells were stimulated with 60 mM caffeine. Left: Representative traces of mitochondrial calcium uptake. Right: Mean of mitochondrial calcium peaks. Results are expressed as mean + / - SD. *Indicates statistically significant differences relative to control myofibers of >20 fibers per condition, P < 0.05 (Student's t-test).

[0029] Fig.13 Figure 2 shows that oleuropein increases mitochondrial respiration in isolated adult mouse muscle fibers (ex vivo). Fibers treated with oleuropein for 2 hours were placed in an XF24 extracellular flux analyzer (Agilent) to measure the oxygen consumption rate during caffeine stimulation. Oligomycin, FCCP, and antimycin / rotenone were added continuously to calculate basal respiration, maximal respiration, ATP-linked, and non-mitochondrial respiration. Results are expressed as mean + / - SD. * Indicates statistically significant differences relative to control muscle fibers of 7 wells under each condition, P < 0.05 (Student's t-test).

[0030] Fig.14 Figure showing that hydroxytyrosol increases mitochondrial respiration in isolated adult mouse muscle fibers (ex vivo). Fibers treated with hydroxytyrosol for 2 hours were placed in an XF24 extracellular flux analyzer (Agilent) to measure the oxygen consumption rate during caffeine stimulation. Oligomycin, FCCP and antimycin / rotenone were added continuously to calculate basal respiration, maximum respiration, ATP-linked and non-mitochondrial respiration. Results are expressed as mean + / - SD. * Indicates statistically significant differences relative to control muscle fibers of 7 wells under each condition, P < 0.05 (Student's t-test).

[0031] Fig.15Figure showing that oleuropein increases fatigue resistance in young rat EDL (extensor digitorum longus) muscle (ex vivo). Muscles incubated in oleuropein showed a significantly slower decrease in force during fatigue compared to muscles to which DMSO was added. The third, fourth, and fifth tetanic stimuli were significantly higher in oleuropein compared to the control, indicating a higher resistance to fatigue. P values ​​are shown at each tetanic contraction. Results are expressed as mean + / - SD. * indicates a statistically significant difference relative to control muscle, P < 0.05 (Student's t-test). Each experiment was repeated in 10 muscles for two experimental groups.

[0032] Fig.16 To show (BioActor BV, NL), Figure showing that olive leaf extracts standardized for their oleuropein content (≥40% oleuropein and <1% hydroxytyrosol (OHT)) promote mitochondrial activation through dephosphorylation of pyruvate dehydrogenase (PDH) in aged rats treated for 3 months. Phospho-PDH and PDH levels were analyzed in gastrocnemius muscle in control animals and 3-month treated animals (inset). Activation of mitochondrial PDH was measured as the ratio between total PDH and phospho-PDH levels. The figure shows the average of muscles from 5 animals. Results are expressed as mean + / - SEM. *Indicates statistically significant differences relative to control (white bars), P < 0.05 (Student's t-test).

[0033] Fig.17 Figure showing that long-term in vivo supplementation of oleuropein (normalized at 40% from olive leaf extract) increases resistance to fatigue in gastrocnemius muscles of adult mice. In the fatigue protocol, oleuropein showed a significantly slower force decrease than DMSO-added muscles, indicating a higher resistance to fatigue. Results are expressed as mean + / - SEM. * indicates a statistically significant difference relative to control muscle, P < 0.05 (Student's t-test). Each experiment was repeated in 10 muscles for two experimental groups.

[0034] Fig.18 Figure 1 shows that long-term in vivo supplementation with oleuropein (normalized at 40% from olive leaf extract) increases the running capacity of young mice. Mice were subjected to a single run on an uphill treadmill. Running capacity was measured as the time spent on the treadmill until the mice were exhausted. The figure shows the mean of 5 animals per group. Results are expressed as mean + / - SEM. * indicates a statistically significant difference relative to control muscle, P < 0.05 (Student's t-test).

[0035] Fig.19Figure 1 shows that long-term in vivo supplementation of oleuropein (normalized at 40% from olive leaf extract) increases running capacity in aged mice. Mice were subjected to a single bout of running on an uphill treadmill. Running capacity was measured as the time spent on the treadmill until the mice were exhausted. The figure shows the mean of 4 animals per group. Results are expressed as mean + / - SEM. * indicates a statistically significant difference relative to control muscle, P < 0.05 (Student's t-test). DETAILED DESCRIPTION

[0036] definition

[0037] Some definitions are provided below. However, definitions may be located in the "Implementation" section below, and the above heading "Definitions" does not indicate that such disclosure in the "Implementation" section is not a definition.

[0038] All percentages expressed herein are by weight of the total weight of the composition, unless otherwise indicated. As used herein, "about", "approximately" and "substantially" should be understood to refer to numbers within a certain numerical range, such as within the range of -10% to +10% of the mentioned number, preferably -5% to +5% of the mentioned number, more preferably -1% to +1% of the mentioned number, and most preferably -0.1% to +0.1% of the mentioned number. All numerical ranges herein should be understood to include all integers or fractions within the range. In addition, these numerical ranges should be understood to provide support for claims involving any number or subset of numbers within the range. For example, the disclosure of 1 to 10 should be understood to support ranges of 1 to 8, 3 to 7, 1 to 9, 3.6 to 4.6, 3.5 to 9.9, etc.

[0039] As used in this disclosure and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a metabolite" or "the metabolite" includes one metabolite, but also includes two or more metabolites.

[0040] The words "including / comprising" will all be interpreted as inclusive rather than exclusive. Likewise, the terms "including / comprising" and "or" should all be considered inclusive unless the context clearly prohibits such an interpretation. However, the compositions disclosed herein may not contain any elements not specifically disclosed herein. Thus, disclosures of embodiments using the term "including / comprising" include disclosures of embodiments "consisting essentially of the specified components" and embodiments "consisting of the specified components."

[0041] As used herein, "a composition consisting essentially of oleuropein or at least one of its metabolites" and "a composition consisting essentially of oleuropein or at least one of its metabolites and calcium" do not include any additional compounds that affect mitochondrial calcium import other than oleuropein or at least one of its metabolites and, optionally, calcium. In a specific non-limiting embodiment, the composition consists of an excipient, at least one of oleuropein or its metabolites, and, optionally, calcium.

[0042] The term "and / or" used in the context of "X and / or Y" should be interpreted as "X" or "Y" or "X and Y". Similarly, "at least one of X or Y" should be interpreted as "X" or "Y" or "both X and Y". For example, "at least one of oleuropein or a metabolite thereof" means "oleuropein" or "a metabolite of oleuropein" or "both oleuropein and a metabolite thereof".

[0043] As used herein, the terms "example" and "such as" (especially when followed by a list of terms) are exemplary and illustrative only and should not be considered exclusive or comprehensive. As used herein, "associated with" and "linked to" refer to co-occurrence, preferably to being caused by the same underlying condition, and most preferably to one of the identified conditions being caused by another identified condition.

[0044] The terms "food," "food product," and "food composition" mean a product or composition that is intended for ingestion by an individual (such as a human) and that provides at least one nutrient to the individual. The compositions of the present disclosure (including the various embodiments described herein) may comprise, consist of, or consist essentially of the following elements: the elements disclosed herein, as well as any additional or optional ingredients, components, or elements described herein or that can be used in a diet.

[0045] As used herein, the term "treatment" refers to applying a composition disclosed herein to a subject with a condition to alleviate, reduce or improve at least one symptom associated with the condition and / or to slow down, reduce or block the progression of the condition. The terms "treatment" and "treat" include both preventive or preventive treatment (preventing and / or delaying the development or progression of a target pathological condition or disorder), as well as curative, therapeutic or disease-modifying treatments, including therapeutic measures that cure, delay, alleviate symptoms of a confirmed pathological condition or disorder and / or interrupt its progression; and treat patients who are at risk of contracting a disease or suspected of contracting a disease, as well as treat patients who are ill or have been diagnosed with a disease or medical condition. The term "treatment" does not necessarily mean that the subject is treated until full recovery. The term "treatment" also refers to health maintenance and / or promotion in individuals who do not suffer from a disease but may be prone to developing an unhealthy condition. The term "treatment" is also intended to include strengthening or otherwise enhancing one or more primary preventive or therapeutic measures. As a non-limiting example, treatment can be performed by a patient, a caregiver, a doctor, a nurse, or another healthcare professional.

[0046] Both human and veterinary treatments are within the scope of the present disclosure. Preferably, oleuropein or at least one of its metabolites is administered in an amount or unit dosage form that provides a therapeutically effective amount or a prophylactically effective amount.

[0047] The term "prevention" refers to administering a composition disclosed herein to a subject that does not show any symptoms of the condition to reduce or prevent the development of at least one symptom associated with the condition. In addition, "prevention" includes reducing the risk, incidence and / or severity of a condition or disorder.

[0048] As used herein, an "effective amount" is an amount that treats or prevents a defect, treats or prevents a disease or medical condition in an individual, or more generally, reduces symptoms, manages disease progression, or provides a nutritional, physiological or medical benefit to the individual.

[0049] The relative terms "improve," "increase," "enhance," and the like refer to the effect of a composition disclosed herein (i.e., a composition comprising an effective amount of at least one of its metabolites) relative to administration within the same time period of a composition that does not contain oleuropein and does not contain oleuropein metabolites but is otherwise identical.

[0050] As used herein, "administering" includes another individual providing the referenced composition to an individual so that the individual can consume the composition, and also includes merely the act of the individual consuming the referenced composition himself.

[0051] "Animal" includes, but is not limited to, mammals, including, but not limited to, rodents; aquatic mammals; livestock, such as dogs, cats, and other pets; farm animals, such as sheep, pigs, cattle, and horses; and humans. When "animal," "mammal," or their plural forms are used, these terms also apply to any animal that is capable of having the effect indicated or intended to be indicated by the context of the paragraph, such as an animal that benefits from improved mitochondrial calcium import. Although the terms "individual" or "subject" are often used herein to refer to humans, the present disclosure is not limited thereto. Therefore, the terms "individual" or "subject" refer to any animal, mammal, or human that can benefit from the methods and compositions disclosed herein.

[0052] The term "pet" means any animal that can benefit from or enjoy the compositions provided by the present disclosure. For example, the pet can be an avian, bovine, canine, equine, feline, caprine, lupine, murine, ovine, or porcine animal, but the pet can be any suitable animal. The term "companion animal" means a dog or a cat.

[0053] In the case of humans, the term "old age" refers to an age of at least 60 years old since birth, preferably more than 63 years old, more preferably more than 65 years old, and most preferably more than 70 years old. In the context of non-human animals, "old age" means a non-human subject that has reached 60% of its possible lifespan, at least 70%, at least 80% or at least 90% of its possible lifespan in some embodiments. The determination of lifespan can be based on mortality statistics, calculations, or estimates, and past, present and future influences or factors known to cause positive or negative impacts on lifespan can be considered. When determining lifespan, species, sex, body size, genetic factors, environmental factors and stressors, current and past health status, past and present nutritional status, and consideration of stressors can be taken into account. In the context of people, the term "middle-aged and elderly" refers to an age of at least 45 years old since birth, preferably more than 50 years old, more preferably more than 55 years old, and includes elderly individuals.

[0054] As used herein, the terms "portion" or "unit dosage form" are interchangeable and refer to physically discrete units suitable as unit dosages for human and animal subjects, each unit preferably containing a predetermined amount of the composition disclosed herein comprising oleuropein or at least one of its metabolites, in association with a pharmaceutically acceptable diluent, carrier or vehicle, in an amount sufficient to produce the desired effect. The specifications for the unit dosage form depend on the specific compound used, the effect to be achieved, and the pharmacodynamics associated with each compound in the host. In one embodiment, the unit dosage form can be a predetermined amount of liquid contained in a container such as a bottle.

[0055] An "oral nutritional supplement" or "ONS" is a composition comprising at least one macronutrient and / or at least one micronutrient, e.g., in sterile liquid, semisolid, or powdered form, and intended to supplement other nutritional intake, such as that from food. Non-limiting examples of commercially available ONS products include and In some embodiments, the ONS may be a beverage in liquid form that can be consumed without further addition of liquid, such as a certain amount of liquid in a serving of the composition.

[0056] As used herein, "incomplete nutrition" preferably refers to a nutritional product that does not contain sufficient amounts of macronutrients (protein, fat and carbohydrates) or micronutrients to be insufficient as a sole source of nutrition for the animal to which the nutritional product is administered. The term "complete nutrition" refers to a product that can be the sole source of nutrition for a subject. From a complete nutritional composition, an individual can obtain 100% of their nutritional requirements.

[0057] "Kit" means that the multiple components of the kit are physically associated in or with one or more containers and are considered a unit for manufacture, distribution, sale, or use. Containers include, but are not limited to, bags, boxes, cartons, bottles, outer packaging, shrink wrap, attached components (e.g., binding components, adhesive components, etc.), packaging of any type, design, or material, or a combination thereof.

[0058] As used herein, preferred embodiments of "exercise" include at least one of: 1) resistance exercise, 2) anaerobic or repeated sprint-type exercise, or 3) endurance exercise.

[0059] Resistance exercise is when an individual undergoes explosive weight movements with long rest periods and is driven primarily by the phospholopatadine and glycolytic energy systems. Resistance exercise produces energy quickly, but individuals fatigue quickly. The main adaptations include increased muscle mass (hypertrophy) by increasing muscle cross-sectional area through repeated weight training. Hakkinen K. 1989. Neuromuscular and hormonal adaptations during strength and powertraining. J. Sports Med. Phys. Fitness. 29: 9-26; and Hakkinen K. et. al. 1987. Relationships between training volume, physical performance capacity, and serum hormone concentrations during prolonged training in elite weight lifters. Int. J. Sports Med. 8 Suppl 1: 61-65.

[0060] Repeated sprint-type training is anaerobic, involves high-intensity exercise with limited recovery periods, and involves almost pure carbohydrate metabolism, with extensive breakdown of muscle glycogen (glycolytic energy production). In these cases of anaerobic energy production, such as high-intensity speed training or exercise involving repeated sprints, the increased load on the muscle is achieved by increasing the firing of type IIa fibers. Finally, under very high workloads, type IIb glycolytic muscle fibers are activated to maintain the high demand for energy supply via anaerobic energy supply. However, during these situations, the high rate of anaerobic energy production exceeds the rate that can be aerobic oxidized within the mitochondria, and this leads to the extreme levels of lactate production present in these types of training situations. Spriet LL, Howlett RA, and Heigenhauser G J. 2000. An enzymatic approach to lactate production in human skeletal muscle during exercise. Med. Sci. Sports Exerc. 32: 756-763.

[0061] Endurance training is characterized by individuals performing low-intensity training for a long time (e.g., >15 minutes). The energy system representative of endurance training includes the aerobic system, which primarily uses aerobic metabolism of fat and carbohydrates to produce the required energy within the mitochondria when sufficient oxygen is present. The main adaptations include increased muscle glycogen storage and glycogen sparing at submaximal workloads via increased fat oxidation, increased lactate kinetics, and morphological changes (including larger type I fibers per muscle area), as well as increased capillary and mitochondrial density. Holloszy JO and Coyle EF. 1984. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J. Appl. Physiol. 56: 831-838; and Holloszy JO, Rennie MJ, Hickson RC, Conlee RK, and Hagberg J M. 1977. Physiological consequences of the biochemical adaptations to endurance exercise. Ann. NYAcad. Sci. 301: 440-450.

[0062] Implementation

[0063] Oleuropein is a polyphenol present in plants belonging to the family Oleaceae, and in particular in the fruit, roots, trunk and more particularly in the leaves of olives. Figure 1 The chemical structure of oleuropein is shown. Oleuropein is 3,4-dihydroxyphenylethanol (also known as hydroxytyrosol, Figure 1 in the Figure 1 Heterosidic esters containing glucose molecules (in Figure 1 marked with "C" in the figure). Figure 2 The metabolic pathways of oleuropein by mammalian and microbial enzymes in the present invention based on the research results reported in the literature are shown.

[0064] One aspect of the present disclosure is a method for preventing or treating exercise-induced muscle fatigue and / or for resisting exercise-induced muscle fatigue. The method comprises orally administering to an individual an effective amount of oleuropein or at least one of its metabolites before, during and / or after exercise. Preferably, the metabolite of oleuropein is selected from the group consisting of oleuropein aglycone, hydroxytyrosol, homovanillyl alcohol, isohomovanillyl alcohol, glucuronidated forms thereof, sulfated forms thereof, derivatives thereof, and mixtures thereof.

[0065] In some embodiments, an effective amount of oleuropein or at least one of its metabolites is administered in a composition selected from the group consisting of a food composition, a dietary supplement, a nutritional composition, a nutraceutical, a beverage, a powdered nutritional product to be reconstituted with water or milk prior to consumption, a food additive, a medicament, a drink, a pet food, and combinations thereof.

[0066] An effective amount of oleuropein or at least one of its metabolites is preferably administered in a composition that also comprises calcium.

[0067] In some embodiments, an effective amount of oleuropein or at least one of its metabolites is administered in a food product further comprising a component selected from the group consisting of protein, carbohydrate, fat, and mixtures thereof.

[0068] The exercise is preferably one or more of the following: 1) resistance exercise, 2) anaerobic or repeated sprint-type exercise, or 3) endurance exercise.

[0069] Another aspect of the present disclosure is a unit dosage form comprising an effective amount of oleuropein or at least one of its metabolites for administration of the unit dosage form before, during and / or after exercise to prevent or treat muscle fatigue caused by the exercise and / or for resisting muscle fatigue caused by exercise. In some embodiments, the unit dosage form (i) consists essentially of oleuropein or at least one of its metabolites, (ii) consists of oleuropein or at least one of its metabolites and an excipient, (iii) consists essentially of oleuropein or at least one of its metabolites and calcium, or (iv) consists of oleuropein or at least one of its metabolites, and an excipient, calcium. Preferably, the exercise is one or more of: 1) resistance exercise, 2) anaerobic or repeated full-speed running type exercise, or 3) endurance exercise.

[0070] Yet another aspect of the present disclosure is a method for preparing a composition for preventing or treating exercise-induced muscle fatigue and / or for resisting exercise-induced muscle fatigue. The method comprises: adding an effective amount of oleuropein or at least one of its metabolites to at least one component selected from protein, carbohydrate and fat. In some embodiments, the method further comprises adding to the at least one component a food additive selected from the following: an acidulant, a thickener, a buffer or reagent for pH adjustment, a chelating agent, a colorant, an emulsifier, an excipient, a flavoring agent, a mineral, an osmotic agent, a pharmaceutically acceptable carrier, a preservative, a stabilizer, a sugar, a sweetener, a texturizing agent, a vitamin, a mineral and a combination thereof. Preferably, the method further comprises adding calcium to the at least one component. Preferably, the exercise is one or more of the following: 1) resistance exercise, 2) anaerobic or repeated full-speed running type exercise, or 3) endurance exercise.

[0071] Another aspect of the present disclosure is a method of achieving at least one result selected from: (i) improving a physiological state associated with metabolic fatigue in one or more cells, (ii) increasing mitochondrial energy and mitochondrial calcium uptake in one or more cells, and (iii) treating or preventing (e.g., reducing incidence and / or severity) calcium deficiency / depletion disorders. The method comprises orally administering to a subject an effective amount of oleuropein or at least one of its metabolites.

[0072] Another aspect of the present disclosure is a method of treating in an individual in need thereof or preventing in an individual at risk (e.g., reducing the incidence and / or severity) of at least one condition selected from: (i) a physiological state associated with metabolic fatigue in one or more cells, and (ii) a calcium deficiency / depletion disorder. The method comprises orally administering to an individual in need thereof or at risk thereof an effective amount of oleuropein or at least one of its metabolites.

[0073] Yet another aspect of the present disclosure is a method for treating or preventing (e.g., reducing the incidence and / or severity) a mitochondrial-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The method comprises orally administering to the individual an effective amount of oleuropein or at least one of its metabolites. The mitochondrial-related disease or condition may be selected from the group consisting of stress, physiological aging, obesity, decreased metabolic rate, metabolic syndrome, diabetes, diabetic complications, hyperlipidemia, neurodegenerative diseases, cognitive impairment, stress-induced or stress-related cognitive dysfunction, mood disorders, anxiety disorders, age-related neuronal death or dysfunction, chronic kidney disease, renal failure, trauma, infection, cancer, hearing loss, macular degeneration, myopathy and malnutrition, and combinations thereof.

[0074] In another embodiment, metabolic fatigue comprises lack of energy, particularly physical energy, lack of vitality, or weakness.

[0075] In some embodiments, the method comprises identifying the individual as having or being at risk for the disorder prior to administering.

[0076] The effective amount of at least one of oleuropein or its metabolites varies with the particular composition, the age and condition of the recipient, and the particular disorder or disease being treated. However, in general embodiments, 0.001 mg to 1.0 g of at least one of oleuropein or its metabolites may be administered to an individual per day, preferably 0.01 mg to 0.9 g of at least one of oleuropein or its metabolites per day, more preferably 0.1 mg to 750 mg of at least one of oleuropein or its metabolites per day, more preferably 0.5 mg to 500 mg of at least one of oleuropein or its metabolites per day, and most preferably 1.0 mg to 200 mg of at least one of oleuropein or its metabolites per day.

[0077] In some embodiments, oleuropein is administered in a composition that also includes calcium. At least a portion of the calcium may be one or more calcium salts, such as calcium acetate, calcium carbonate, calcium chloride, calcium citrate, calcium gluconate, calcium gluconate, calcium lactate, or mixtures thereof. In a general embodiment, 0.1 g to 1.0 g of calcium is administered to an individual per day, preferably 125 mg to 950 g of calcium per day, more preferably 150 mg to 900 mg of calcium per day, more preferably 175 mg to 850 mg of calcium per day, and most preferably 200 mg to 800 mg of calcium per day.

[0078] In one embodiment, at least a portion of oleuropein is obtained by extraction, for example by extraction from plants such as plants belonging to the family Oleaceae, preferably from plants belonging to the family Oleaceae such as olive (olive tree), plants of the genus Ligustrum, plants of the genus Syringa, plants of the genus Fraxinus, plants of the genus Jasminum and plants of the genus Oleaceae One or more of the stems, leaves, fruits or cores. Additionally or alternatively, at least a portion of oleuropein and / or its metabolites may be obtained by chemical synthesis.

[0079] Non-limiting examples of suitable metabolites of oleuropein include oleuropein aglycone, hydroxytyrosol, homovanillyl alcohol, isohomovanillyl alcohol, glucuronidated forms thereof, sulfated forms thereof, derivatives thereof, and mixtures thereof. FIG3A shows the chemical structure of homovanillyl alcohol; and Figure 3B Its isomers (3-hydroxy-4-methoxyphenethyl alcohol or 3-hydroxy-4-methoxyphenethyl alcohol) are shown.

[0080] In some embodiments, oleuropein or at least one of its metabolites is the only polyphenol administered to the subject and / or the only polyphenol in a composition administered to the subject.

[0081] In some embodiments, oleuropein or at least one of its metabolites and optionally calcium may be administered to an elderly individual. In some embodiments, the individual is healthy. In some embodiments, the individual has metabolic fatigue, but is optionally otherwise healthy. In some embodiments, the individual may be a pet.

[0082] In one embodiment, at least a portion of the one or more cells is a portion of at least one body part selected from the group consisting of liver, kidney, brain, and skeletal muscle.

[0083] Oleuropein or at least one of its metabolites and optionally calcium can be administered in any composition suitable for human and / or animal consumption. In a preferred embodiment, oleuropein or at least one of its metabolites and optionally calcium are administered orally or enterally (e.g., by tube feeding) to the individual. For example, oleuropein or at least one of its metabolites and optionally calcium can be administered to the individual in a beverage, food product, capsule, tablet, powder, or suspension.

[0084] Non-limiting examples of suitable compositions include food compositions, dietary supplements, dietary supplements (e.g., liquid ONS), complete nutritional compositions, beverages, pharmaceuticals, nutraceuticals, powdered nutritional products to be reconstituted with water or milk before consumption, food additives, medicaments, drinks, pet foods, and combinations thereof.

[0085] Food products according to the invention may include dairy products, such as fermented milk products, e.g. yoghurt, buttermilk etc.; ice cream; condensed milk; milk; dairy cream; flavoured milk drinks; whey-based drinks; toppings; coffee creamer; chocolate; cheese-based products; soups; sauces; purees; condiments; puddings; custards; baby foods; nutritional formulas, such as those for complete nutrition, e.g. for infants, children, teenagers, adults, the elderly or the critically ill; e.g. cereals and cereal bars.

[0086] The drinks may include, for example, milk- or yoghurt-based drinks, fermented milks, protein drinks, coffee, tea, energy drinks, soy drinks, fruit and / or vegetable drinks, fruit and / or vegetable juices.

[0087] The at least one of oleuropein or its metabolites and optionally calcium may be administered in a food product further comprising a component selected from the group consisting of protein, carbohydrates, fat, and mixtures thereof.

[0088] In some cases where oral or enteral administration is not possible or advisable, the composition may be administered parenterally.

[0089] In another embodiment, the present disclosure provides a method for treating or preventing (e.g., reducing the incidence and / or severity) a mitochondrial-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The method comprises orally administering to an individual in need thereof or at risk thereof an effective amount of oleuropein or at least one of its metabolites.

[0090] In one embodiment, oleuropein or at least one of its metabolites, and optionally calcium, are administered to the individual for a period of at least one month; preferably at least two months, more preferably at least three, four, five, or six months; and most preferably at least one year. During this period, oleuropein or at least one of its metabolites, and optionally calcium, may be administered to the individual at least one day per week; preferably at least two days per week, more preferably at least three, four, five, or six days per week; and most preferably seven days per week. Oleuropein or at least one of its metabolites, and optionally calcium, may be administered in a single dose per day or in multiple separate doses per day.

[0091] The above application examples do not require continuous daily application without interruption. Instead, there may be some brief interruptions in the application, such as two to four days of interruption during the application. The ideal duration of application of the composition can be determined by those skilled in the art.

[0092] In one embodiment, oleuropein or at least one of its metabolites may be administered with calcium in the same composition, such as a unit dosage form comprising both oleuropein or at least one of its metabolites and calcium.

[0093] In an alternative embodiment, oleuropein or at least one of its metabolites may be administered sequentially with calcium in separate compositions. The term "sequentially" means that at least one of oleuropein or its metabolites and calcium are administered in a sequential manner, such that at least one of oleuropein or its metabolites is administered without calcium at a first time, and calcium is administered without at least one of oleuropein or its metabolites at a second time (before or after the first time). The time between sequential administrations may be, for example, one or more seconds, one or more minutes, or one or more hours in the same day; one or more days, one or more weeks in the same month; or one or more months in the same year.

[0094] Another aspect of the present disclosure is a method of preparing a composition for achieving an effect selected from the group consisting of: (i) improving a physiological state associated with metabolic fatigue in one or more cells, (ii) increasing mitochondrial energy and mitochondrial calcium uptake in one or more cells, and (iii) treating or preventing (e.g., reducing incidence and / or severity) a calcium deficiency / depletion disorder.

[0095] The method comprises adding at least one of oleuropein or its metabolites to an ingredient selected from proteins, carbohydrates, lipids, and combinations thereof. The composition (e.g., food product) can be prepared prior to administration (e.g., the composition is prepared, packaged, and then purchased by a consumer who administers the composition to themselves or another individual), or can be prepared substantially simultaneously with administration (the composition is prepared by an individual who administers the composition to themselves or another person less than 30 minutes prior to administration, preferably less than 15 minutes prior to administration, more preferably less than 10 minutes prior to administration, and most preferably less than 5 minutes prior to administration).

[0096] The composition may include an effective amount of oleuropein or at least one of its metabolites. For example, a single serving or dose of the composition may include an effective amount, and the package may include one or more servings, or one or more doses. Optionally, the composition may also include calcium.

[0097] The composition may comprise a food additive selected from the group consisting of acidulants, thickeners, buffers or agents for pH adjustment, chelating agents, colorants, emulsifiers, excipients, flavoring agents, minerals, osmotic agents, pharmaceutically acceptable carriers, preservatives, stabilizers, sugars, sweeteners, texturizers, vitamins, minerals, and combinations thereof.

[0098] In addition to oleuropein or at least one of its metabolites and optionally calcium, the composition may further comprise a protein source from animal or vegetable origin, such as milk protein, soy protein and / or pea protein. In a preferred embodiment, the protein source is selected from the group consisting of whey protein; casein protein; pea protein; soy protein; wheat protein; corn protein; rice protein; protein from legumes, cereals and grains; and combinations thereof. Additionally or alternatively, the protein source may comprise protein from nuts and / or seeds.

[0099] The protein source preferably comprises whey protein. The whey protein may be unhydrolyzed or hydrolyzed whey protein. The whey protein may be any whey protein, for example, the whey protein may be selected from whey protein concentrate, whey protein isolate, whey protein micelles, whey protein hydrolysates, acid whey, sweet whey, modified sweet whey (sweet whey from which casein-glycomacropeptide has been removed), fractions of whey protein and any combination thereof. In a preferred embodiment, the whey protein comprises whey protein isolate and / or modified sweet whey.

[0100] As mentioned above, the protein source may be from an animal or plant source, such as milk protein, soy protein and / or pea protein. In one embodiment, the protein source comprises casein. Casein may be obtained from any mammal, but is preferably obtained from cow's milk, and is preferably micellar casein.

[0101] The composition may include one or more branched-chain amino acids. For example, the composition may include leucine, isoleucine and / or valine. The protein source in the composition may include leucine in free form and / or leucine (such as dairy, animal or plant protein) bound to peptides and / or proteins. In one embodiment, the composition includes leucine in an amount up to 10% by weight of the dry matter of the composition. Leucine can be present in the form of D-leucine or L-leucine, preferably in the L-form. If the composition includes leucine, the composition can be administered in a daily dose of 0.01 to 0.04 g leucine per kg body weight, preferably 0.02 to 0.035 g leucine per kg body weight. Such dosages are particularly suitable for complete nutritional compositions, but ordinary technicians will easily recognize how to adjust these dosages for oral nutritional supplements (ONS).

[0102] One or more other minerals other than any calcium may be used in the composition. Non-limiting examples of suitable minerals include boron, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, nickel, phosphorus, potassium, selenium, silicon, tin, vanadium, zinc, and combinations thereof.

[0103] One or more other vitamins other than any may be used in the composition. Non-limiting examples of suitable vitamins include vitamin A, vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin or niacinamide), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine, pyridoxal, pyridoxamine or pyridoxine hydrochloride), vitamin B7 (biotin), vitamin B9 (folic acid) and vitamin B12 (various cobalamines; typically cyanocobalamin in vitamin supplements), vitamin C, vitamin D, vitamin E, vitamin K, folic acid, biotin) and combinations thereof. "Vitamins" include such compounds, provitamins, derivatives thereof, and analogs thereof, obtained naturally from plant and animal foods or prepared synthetically.

[0104] The composition may also include carbohydrate and / or fat sources. Non-limiting examples of suitable fats include canola oil, corn oil and high oleic sunflower oil. Non-limiting examples of suitable carbohydrates include sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin and mixtures thereof. In addition or alternatively, dietary fiber may be added. Dietary fiber passes through the small intestine without being digested by enzymes and functions as a natural filler and laxative. Dietary fiber may be soluble or insoluble, and generally speaking a mixture of two types is preferred. Non-limiting examples of suitable dietary fiber include soybean, pea, oat, pectin, guar gum, partially hydrolyzed guar gum, gum arabic, oligofructose, acid oligosaccharides, oligogalactose, sialyllactose and oligosaccharides from animal milk. A preferred fiber mixture is a mixture of inulin and shorter chain oligofructose. In one embodiment, the fiber content is between 2 and 40 g / L composition, for example, between 4 and 10 g / L.

[0105] One or more food grade emulsifiers such as diacetyl tartaric acid esters of mono- and di-glycerides, lecithin and / or mono- and di-glycerides may be incorporated into the composition. Suitable salts and stabilizers may also be included.

[0106] Example

[0107] The following non-limiting examples provide experimental data supporting the compositions and methods disclosed herein.

[0108] Example 1

[0109] To test the effects of oleuropein, its metabolites, and calcium supplementation / deficiency in living cells, the inventors measured mitochondrial calcium elevation in HeLa cells and in myotubes differentiated from mouse C2C12 cells and human primary adult muscle cells. HeLa cells and C2C12 cells were purchased from ATCC. Human skeletal muscle myoblasts (HSMM) were purchased from Lonza. HSMM were isolated from the upper arm or leg muscle tissue of normal donors and used after the second passage. HeLa cells were seeded in 96-well plates of basic essential medium (DMEM, Gibco) (high glucose + 10% fetal bovine serum) at a density of 50,000 cells / well. C2C12 cells were seeded in 96-well plates of DMEM high glucose (Gibco) + 10% fetal bovine serum at a density of 8,000 cells / well. Myotubes were differentiated from C2C12 cells by growing the cells in DMEM containing 2% horse serum for 4 days. HSMM were seeded at a density of 8000 cells / well in DMEM / F-12 (Gibco) in 96-well plates. Myotubes were differentiated into HSMM by growing the cells for 4 days in SKM-M medium (ZenBio) containing 2% horse serum.

[0110] Mitochondrial calcium measurements were performed using HeLa cells or myotubes infected with adenovirus expressing the mitochondrial-targeted calcium sensor mitochondrial mutant aequorin (from Sirion biotech) (Monange et al., 2004). For aequorin reconstitution, 24 hours after infection, cells or myotubes were incubated for 2 hours at room temperature (22 ± ℃) in standard medium (145 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM MgCl2, 10 mM glucose and 10 mM Hepes, pH 7.4) with 1 μM wild-type coelenterazine.

[0111] For treatment, the compound was added directly to the cell culture or myotube culture 2 hours before measurement. Luminescence was measured at Cytation 3 cell imaging reader (Biotek) or FLIPR Tetra Aequorin (Molecular Devices). Optical density data were calibrated to calcium concentration (Alvarez & Montero, 2002) using the algorithm as described above. Custom modules based on Excel (Microsoft) and GraphPad Prism 7.02 (GraphPad) software were used for quantitative analysis.

[0112] like Figure 4 As shown, oleuropein increased the rise in mitochondrial calcium in HeLa cells during stimulation. Figure 5 As shown in Figure 2, oleuropein activated mitochondrial calcium in caffeine-stimulated human myotubes differentiated from human skeletal muscle myoblasts (HSMM). Figure 6 As shown, phenolic metabolites of oleuropein activated mitochondrial calcium in caffeine-stimulated HSMM myotubes. Figure 7 As shown, Ca 2+ Supplementation activates mitochondrial Ca in a dose / response manner in C2C12-derived myotubes 2+ Increase. Figure 8 As shown, oleuropein rescued mitochondrial activation under calcium-depleted conditions in C2C12-derived myotubes.

[0113] Example 2

[0114] To test the effects of oleuropein and hydroxytyrosol on mitochondrial respiration and to evaluate the effects of these compounds on the ATP synthase-dependent components of respiration, the inventors measured oxygen consumption in human skeletal muscle myotubes. For respiration experiments, oxygen consumption was measured in myotubes using an XF96 instrument (Seahorse Biosciences, MA). On the 2nd day and after the 2nd day, human myotubes were seeded into Seahorse tissue plates coated with poly-ornithine, and the cells were washed twice in Krebs-Ringer bicarbonate Hepes buffer (KRBH) containing (in mM) 140NaCl, 3.6Kcl, 0.5NaH2PO4, 0.5MgSO4, 1.5CaCl2, 10Hepes, 5NaHCO3, 10 glucose, pH7.4. The respiratory rate was measured every 6 minutes at 37°C. ATP synthase-dependent respiration was calculated as the difference between the respiratory rates before and after the addition of oligomycin. The experiment was performed at 37°C.

[0115] like Fig. 9 Shown, oleuropein and hydroxytyrosol promote the ATP synthase-dependent component of respiration during stimulation in human skeletal muscle myotubes.

[0116] Example 3

[0117] To test the effect of oleuropein on ATP production, the inventors measured ATP in myotubes differentiated from C2C12 cells. ATP was measured using a conventional luminescence-based luciferin / luciferase method. Myotubes were incubated in KRBH medium and oleuropein was added for 15 minutes. Myotubes were then stimulated with 5 mM caffeine for an additional 10 minutes. Finally, myotubes were incubated with luciferin / luciferase in lysis buffer and the bioluminescent signal, which is proportional to the amount of ATP present, was measured at a Cytation 3 cell imaging reader (Biotek). Fig.10 As shown, oleuropein increased ATP production in C2C12-derived myotubes stimulated with caffeine.

[0118] Example 4

[0119] To test the effects of oleuropein and hydroxytyrosol on mitochondrial calcium uptake in isolated adult mouse muscle fibers, flexor digitorum brevis (FDB) fibers were isolated 7-10 days after in vivo transfection. Muscles were digested in collagenase A (4 mg / ml) (Roche) dissolved in Tyrode's salt solution (pH 7.4) (Sigma-Aldrich) containing 10% fetal bovine serum (ThermoFisher Scientific). Single fibers were isolated, plated on laminin-coated coverslips, and cultured in DMEM with HEPES (42430 Thermo Fisher Scientific) supplemented with 10% fetal bovine serum containing penicillin (100 U / ml), streptomycin (100 μg / ml). Fibers were maintained in culture at 37°C and 5% CO2. For mitochondrial Ca 2+ Measurement, FDB muscle was electroporated with a plasmid encoding the mitochondrial calcium sensor 4mtGCaMP6f. After single fiber separation, real-time imaging was performed. During the experiment, at room temperature, in the presence of 75 μM N-benzyl-toluenesulfonamide (BTS, Sigma-Aldrich), the muscle fibers were kept in Krebs-Ringer modified buffer (135mM NaCl, 5mM KCl, 1mMMgCl2, 20mM HEPES, 1mM MgSO4, 0.4mM KH2PO4, 1mM CaCl2, 5.5mM glucose, pH7.4) to avoid fiber contraction. When the indication triggered calcium release from intracellular reservoirs, 60mM caffeine (Sigma-Aldrich) was added. Experiments were performed on a Zeiss Axiovert 200 microscope equipped with a 40× / 1.3NA. PlanFluor objective lens. Excitation was performed using a DeltaRAM V high-speed monochromator (Photon Technology International) equipped with a 75W xenon arc lamp. Images were captured using a high-sensitivity Evolve 512Delta EMCCD (Photometrics). The system was controlled by MetaMorph 7.5 (Molecular Devices) and assembled by Crisel Instruments. Alternatively, the 4mtGCaMP6f sensor was excited at 410 nm and 475 nm per second, respectively, and images were acquired through dual-band emission filters (520 / 40 and 630 / 60 (Chroma). The exposure time was set to 50 ms. Acquisition was performed at binning 1 with an EM gain of 200. Image analysis was performed using the Fiji distribution of ImageJ software. The background of the images was subtracted. As Fig.11 As shown, oleuropein increased mitochondrial calcium uptake in isolated adult mouse muscle fibers. Fig.12As shown, oleuropein increased mitochondrial calcium uptake in isolated adult mouse muscle fibers.

[0120] Example 5

[0121] To test the effects of oleuropein and hydroxytyrosol on mitochondrial respiration in isolated adult mouse muscle fibers, flexor digitorum brevis (FDB) fibers were isolated as follows. Muscles were digested in collagenase A (4 mg / ml) (Roche) dissolved in Tyrode's salt solution (pH 7.4) (Sigma-Aldrich) containing 10% fetal bovine serum (Thermo Fisher Scientific). Single fibers were isolated, plated on laminin-coated XF24 microplates and cultured in DMEM (D5030 Sigma-Aldrich) supplemented with 1 mM sodium pyruvate, 5 mM glucose, 33 mM NaCl, 15 mg phenol red, 25 mM HEPES, 1 mM L-Glu in the presence of 75 μM N-benzyl-p-toluenesulfonamide (BTS, Sigma-Aldrich). Fibers were maintained in culture at 37° C. in 5% CO2 for 2 hours. Oxygen consumption rate was assessed in real time with an XF24 Extracellular Flux Analyzer (Agilent), which allows measurement of changes in oxygen consumption rate (OCR) after up to four consecutive additions of compound. Titrations were performed with decoupler FCCP in order to utilize the FCCP concentration that maximized the increase in OCR (0.6 μM). To measure the effect of oleuropein or hydroxytyrosol on stimulated respiration, fibers were stimulated with 10 mM caffeine. To assess the ATP synthase-dependent component of respiration, oligomycin (2 The results were normalized to the fluorescence of calcein (Sigma-Aldrich). The fibers were loaded with 2 μM calcein for 30 min. Fluorescence was measured using a Perkin Elmer EnVision plate reader in well scanning mode using a 480 / 20 nm filter for excitation and a 535 / 20 nm filter for emission. Fig.13 As shown, oleuropein increased stimulated mitochondrial respiration and the ATP synthase-dependent component of respiration in isolated adult mouse muscle fibers. Fig.14 As shown, hydroxytyrosol increases stimulated mitochondrial respiration and ATP synthase-dependent respiration in isolated adult mouse muscle fibers.

[0122] Example 6

[0123] To test the acute effect of oleuropein on muscle fatigue in healthy adult mice, extensor digitorum longus (EDL) muscles were dissected from tendon to tendon under a stereomicroscope and mounted between force transducers (KG Scientific Instruments, Heidelberg, Germany) in a small chamber in which oxygenated Krebs solution was circulated continuously and the temperature was maintained at 25 °C. The stimulation conditions were optimized and the length of the muscle was increased until the force development during 90 Hz stimulation was maximized. After measuring the first force-frequency relationship, oleuropein was added to the culture medium at a final concentration of 10 μM. Next, the force-frequency was determined every 10 minutes until one hour after the addition. After one hour, a fatigue protocol was applied, which consisted of 120 tetanic contractions (100 Hz) of a duration of 300 ms repeated per second. Fatigue was determined as a decrease in force relative to the initial force. Each experiment was repeated in 10 muscles for both experimental groups. As Fig.15 As shown, muscles incubated in oleuropein displayed a significantly slower force decrease during fatigue compared to control muscles, indicating increased fatigue resistance.

[0124] Example 7

[0125] To test the effect of olive leaf extracts standardized for their oleuropein content (≥40% oleuropein) on mitochondrial activation via dephosphorylation of pyruvate dehydrogenase (PDH), (BioActor BV, NL) supplemented 20 month rats for 3 months, then analyzed gastrocnemius muscle by Western. The content of PDH and phospho-PDH was quantified. In order to monitor protein levels, Qiagen Tissue Lyser was used to crush frozen muscles, and protein extracts were prepared in appropriate buffers, which contained: muscle lysis buffer (50mM Tris pH 7.5, 150mM NaCl, 5mM MgCl2, 1mM DTT, 10% glycerol, 2% SDS, 1% Triton X-100, complete protease inhibitor mixture (Roche) without EDTA, 1mM PMSF, 1mM NaVO3, 5mM NaF and 3mM β-glycerophosphate). 40 μg of total protein was quantitatively loaded according to BCA. Proteins were separated by SDS-PAGE electrophoresis in commercial 4%-12% acrylamide gel (Thermo Fisher Scientific), and proteins were transferred to nitrocellulose membranes (Thermo Fisher Scientific) by wet electrophoretic transfer. The blots were blocked with 5% skim milk powder (Bio-Rad) in TBS-tween (0.5 M Tris, 1.5 M NaCl, 0.01% Tween) solution for 1 h at room temperature and incubated with primary antibodies at 4 °C. The secondary antibodies were incubated for 1 h at room temperature. The following antibodies were used: anti-phospho-PDH (1:5000, Abcam), anti-PDH (1:1000, Cell Signaling). HRP-conjugated secondary antibodies were purchased from Bio-Rad and used at a dilution of 1:5000. Activation of mitochondrial PDH was measured as the ratio between total PDH and phospho-PDH levels. Fig.16 As shown, (BioActor BV, NL), supplemented with (BioActor BV, NL) promotes mitochondrial activation by dephosphorylation of pyruvate dehydrogenase in 3-month-old rats.

[0126] Example 8

[0127] Experimental and conditions concerning the beneficial effects of oleuropein in vivo in the setting of muscle fatigue. Figure 17-19 There are different graphs representing three different conditions (one graph with electrophysiological phenomena, two on a treadmill).

[0128] To test the long-term effects of oleuropein on muscle fatigue in healthy adult mice ( Fig.17), 2-month-old mice were supplemented daily for 4 weeks with olive leaf extract standardized for oleuropein content (20 mg / kg / day oleuropein). The fatigue protocol was performed in the gastrocnemius muscle and consisted of a 100 Hz series of 0.5 seconds per second for 60 seconds. Fatigue was determined electrophysiologically as a decrease in force relative to the initial force. Force was normalized to muscle weight. Fig.17 It was shown that oleuropein (standardized at 40% from olive leaf extract, OLE) increased resistance to fatigue in young mice after chronic treatment.

[0129] In order to test the long-term effect of oleuropein on running performance in the endurance treadmill test of healthy adult mice, 3-month-old mice were supplemented with olive leaf extract, and the oleuropein content of olive leaf extract was standardized (20mg / kg / day oleuropein) for 4 weeks. Control mice were treated with a common feed diet. Mice were adapted to a 10° uphill LE8700 treadmill (Harvard apparatus) and trained on it for 2 days. On the 1st day, mice ran for 5 minutes at a speed of 8 meters / minute, and on the 2nd day, mice ran for 5 minutes at a speed of 8 meters / minute, and then ran for another 5 minutes at a speed of 10 meters / minute. On the 3rd day, mice were subjected to a single run starting at a speed of 10m / min. Ten minutes later, the treadmill speed was increased at a rate of 2 meters / minute per 5 minutes until the mice were exhausted. Exhaustion is defined as the point at which mice spend more than 5 seconds on the electric vibrator without attempting to resume running. The total running time of each mouse was recorded.

[0130] Fig.18 Figure showing that oleuropein (standardized at 40% from olive leaf extract) increases running ability in young mice after chronic treatment. To test the long-term effects of oleuropein on running performance in an endurance treadmill test in aged mice, 20 month old mice were supplemented with olive leaf extract standardized for oleuropein content (20 mg / kg / day oleuropein) for 4 weeks. Control mice were treated with a normal chow diet. Young mice were experimented as described above.

[0131] Fig.19 Graph showing that oleuropein (standardized at 40% from olive leaf extract) increases running capacity in chronically treated aged mice.

[0132] References

[0133] Alvarez, J., & Montero, M. (2002). Measuring [Ca2+] in the endoplasmicreticulum with aequorin. Cell Calcium, 32(5-6), 251-260.

[0134] Montero, M., Lobaton, CD, Hemandez-Sanmiguel, E., Santodomingo, J., Vay, L., Moreno, A., & Alvarez, J. (2004). Direct activation of the mitochondrial calcium uniporter by natural plant flavonoids. Biochem J, 384 (Pt 1), 19-24.doi:10.1042 / BJ20040990

[0135] It should be understood that various changes and modifications made to the presently preferred embodiments described herein will be apparent to those skilled in the art. These changes and modifications may be made without departing from the spirit and scope of the subject matter of the present invention and without diminishing its intended advantages. Therefore, such changes and modifications are intended to be covered by the appended claims.

Claims

1. A method for preventing or treating exercise-induced muscle fatigue and / or for resisting exercise-induced muscle fatigue, the method comprising orally administering to an individual an effective amount of oleuropein or at least one of its metabolites before, during and / or after exercise.

2. The method according to claim 1, wherein the metabolite of oleuropein is selected from the group consisting of oleuropein, hydroxytyrosol, homovanillyl alcohol, isohomovanillyl alcohol, glucuronidated forms thereof, sulfated forms thereof, derivatives thereof, and mixtures thereof.

3. The method of claim 1 or claim 2, wherein the effective amount of oleuropein or at least one of its metabolites is administered in a composition selected from the group consisting of a food composition, a dietary supplement, a nutritional composition, a nutraceutical, a beverage, a powdered nutritional product to be reconstituted with water or milk before consumption, a food additive, a medicament, a drink, a pet food, and combinations thereof.

4. The method of any one of claims 1 to 3, wherein the effective amount of oleuropein or at least one of its metabolites is administered in a composition further comprising calcium.

5. The method according to any one of claims 1 to 4, wherein the effective amount of oleuropein or at least one of its metabolites is administered in a food product further comprising a component selected from the group consisting of protein, carbohydrates, fat, and mixtures thereof.

6. The method of any one of claims 1 to 5, wherein the exercise is one or more of: 1) resistance exercise, 2) anaerobic or repeated sprint-type exercise, or 3) endurance exercise.

7. A unit dosage form comprising an effective amount of oleuropein or at least one of its metabolites, for administration of the unit dosage form before, during and / or after exercise, thereby preventing or treating muscle fatigue induced by the exercise and / or for resisting muscle fatigue induced by exercise.

8. The unit dosage form of claim 7, consisting essentially of at least one of said oleuropein or a metabolite thereof.

9. The unit dosage form according to claim 7 or claim 8, consisting of at least one of oleuropein or its metabolites and an excipient.

10. The unit dosage form according to any one of claims 7 to 9, consisting essentially of said at least one of oleuropein or a metabolite thereof and calcium.

11. The unit dosage form according to any one of claims 7 to 10, consisting of at least one of oleuropein or its metabolites, and excipients, calcium.

12. The unit dosage form according to any one of claims 7 to 11, wherein the exercise is one or more of the following: 1) resistance exercise, 2) anaerobic or repeated sprint-type exercise, or 3) endurance exercise.

13. A method for preparing a composition for preventing or treating exercise-induced muscle fatigue and / or for resisting exercise-induced muscle fatigue, the method comprising adding an effective amount of oleuropein or at least one of its metabolites to at least one component selected from protein, carbohydrate and fat.

14. The method of claim 13, further comprising adding to the at least one ingredient a food additive selected from the group consisting of acidulants, thickeners, buffers or agents for pH adjustment, chelating agents, colorants, emulsifiers, excipients, flavoring agents, minerals, osmotic agents, pharmaceutically acceptable carriers, preservatives, stabilizers, sugars, sweeteners, texturizers, vitamins, minerals, and combinations thereof.

15. The method of claim 13 or claim 14, further comprising adding calcium to the at least one ingredient.

16. The method of any one of claims 13 to 15, wherein the exercise is one or more of: 1) resistance exercise, 2) anaerobic or repeated sprint-type exercise, or 3) endurance exercise.